Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

Journal of Clinical Investigation

Volumn 115, Issue 3, 2005, Pages 739-746

  Speiser, Daniel E ^a,e   Liénard, Danielle ^a   Rufer, Nathalie ^b   Rubio Godoy, Verena ^a   Rimoldi, Donata ^a   Lejeune, Ferdy ^a   Krieg, Arthur M ^c   Cerottini, Jean Charles ^a,d   Romero, Pedro ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c PFIZER INC   (United States)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDYL DEOXYGUANOSIN OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; GAMMA INTERFERON; GRANZYME B; HLA A2 ANTIGEN; MELAN A; OLIGONUCLEOTIDE; PERFORIN; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; CELL CLONE; CELL MATURATION; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ERYTHEMA; EX VIVO STUDY; FATIGUE; HEADACHE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INJECTION PAIN; LOW DRUG DOSE; MALAISE; MELANOMA; MEMORY CELL; MYALGIA; NAUSEA; PRIORITY JOURNAL; SKIN INDURATION; T LYMPHOCYTE; VACCINATION;

EID: 14644390867     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23373     Document Type: Article

References (51)

1. Janeway, C.A., Jr. 1989. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54:1-13.
2. Marrack, P., and Kappler, J. 1994. Subversion of the immune system by pathogens. Cell 76:323-332.
3. Medzhitov, R., and Janeway, C.A., Jr. 1997. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9:4-9.
4. Akira, S., Takeda, K., and Kaisho, T. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-680.
5. Kadowaki, N., et al. 2001. Subsets of human dendritic cell precursors express different toll-like recepcors and respond to different microbial antigens. J. Exp. Med. 194:863-869.
6. Steinman, R.M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
7. Klinman, D.M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4:249-259.
8. Hemmi, H., et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature. 408:740-745.
9. Takeshita, F., et al. 2001. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167:3555-3558.
10. Weiner, G.J., Liu, H.M., Wooldridge, J.E., Dahle, C.E., and Krieg, A.M. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U. S. A. 94:10833-10837.
11. Lipford, G.B., et al. 1997. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:2340-2344.
12. Oxenius, A., Martinic, M.M., Hengartner, H., and Klenerman, P. 1999. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J. Virol. 73:4120-4126.
13. Vabulas, R.M., Pircher, H., Lipford, G.B., Hacker, H., and Wagner, H. 2000. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J. Immunol. 164:2372-2378.
14. Davila, E., and Celis, E. 2000. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/ protein immunizacion results in enhanced CTL responses with anti-tumor activity. J. Immunol. 165:539-547.
15. Miconnet, I., et al. 2002. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168:1212-1218.
16. Hartmann, G., et al. 2000. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:1617-1624.
17. Bauer, S., et al. 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U. S. A. 98:9237-9242.
18. Krieg, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
19. Davis, H.L., et al. 2000. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 18:1920-1924.
20. Halperin, S.A., et al. 2003. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 21:2461-2467.
21. Cormier, J.N., et al. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:37-44.
22. Pullarkat, V., et al. 2003. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin. Cancer Res. 9:1301-1312.
23. Liénard, D., et al. 2004. Ex vivo detectable activation of Melan-A specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunity. 4:4.
24. Rosenberg, S.A., et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
25. Schaed, S.G., et al. 2002. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res. 8:967-972.
26. Speiser, D.E., et al. 2003. Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immunity. 3:12.
27. Speiser, D.E., et al. 2004. Ex vivo analysis of human antigen specific CD8+ T cell responses: Quality assessment of fluorescent HLA-A2 multimers and IFN gamma Elispot assays for patient immune monitoring. J. Immunother. 27:298-308.
28. Kawabe, Y., and Ochi, A. 1991. Programmed cell death and extrathymic reduction of Vβ8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature. 349:245-248.
29. Lenardo, M., et al. 1999. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17:221-253.
30. Blattman, J.N., et al. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540-547.
31. Romero, P., et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188:81-96.
32. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708-712.
33. Rufer, N., et al. 2003. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood. 102:1779-1787.
34. Boon, T., and Van den Eynde, B. 2003. Tumour immunology. Curr. Opin. Immunol. 15:129-130.
35. Monsurro, V., et al. 2001. Kinetics of TCR use in response to repeated epitope-specific immunization. J. Immunol. 166:5817-5825.
36. Jaeger, E., et al. 1996. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo, implications for tumor vaccines with melanoma associated antigens. Int. J. Cancer. 66:162.
37. Speiser, D.E., et al. 2003. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor specific T cells. Semin. Cancer Biol. 13:461-472.
38. Powell, D.J., Jr., and Rosenberg, S.A. 2004. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J. Immunother. 27:36-47.
39. Heikenwalder, M., et al. 2004. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10:187-192.
40. Sparwasser, T., et al. 1999. Immunostimulacory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J. Immunol. 162:2368-2374.
41. Salio, M., Palmowski, M.J., Atzberger, A., Hermans, I.F., and Cerundolo, V. 2004. CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J. Exp. Med. 199:567-579.
42. Pittet, M.J., et al. 1999. High frequencies of naive Melan-A/MART-1- specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:705-715.
43. Yu, P., et al. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5:141-149.
44. Houghton, A.N. 2004. LIGHTing the way for tumor immunity. Nat. Immunol. 5:123-124.
45. Verthelyi, D., Ishii, K.J., Gursel, M., Takeshita, F., and Klinman, D.M. 2001. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 166:2372-2377.
46. Hartmann, G., et al. 2003. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33:1633-1641.
47. Marshall, J.D., et al. 2003. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 73:781-792.
48. Vollmer, J., et al. 2004. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34:251-262.
49. Akbar, A.N., Lord, J.M., and Salmon, M. 2000. IFN-alpha and IFN-beta: a link between immune memory and chronic inflammation. Immunol. Today. 21:337-342.
50. Sprent, J., and Surh, C.D. 2002. T cell memory. Annu. Rev. Immunol. 20:551-579.
51. Altman, J.D., et al. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:94-96.